Lehr Martin A. 4
4 · Context Therapeutics Inc. · Filed Feb 23, 2026
Research Summary
AI-generated summary of this filing
Context Therapeutics (CNTX) CEO Martin A. Lehr Receives Award
What Happened
- Martin A. Lehr, Chief Executive Officer of Context Therapeutics (CNTX), received a derivative equity award covering 815,000 shares on February 19, 2026. The award was reported as acquired at $0.00 (i.e., no cash paid at grant) and is a grant/award (transaction code A), not an immediate sale or exercised option.
Key Details
- Transaction date: 2026-02-19; filing date: 2026-02-23 (timely filing).
- Amount: 815,000 derivative shares (award/option) granted; reported acquisition price $0.00.
- Shares owned following transaction: not specified in the Form 4 filing.
- Footnote: The award vests over four years — 25% on February 19, 2027, then monthly vesting over the remaining three years, subject to continued service (per filing footnote).
- Filing timeliness: Report filed within the required reporting window; not flagged as late.
Context
- This was an award of derivative securities (an equity grant/option), not an exercise or sale. The grant creates potential future ownership as the award vests; no shares were sold or exercised at grant date.
- Such grants are typically part of executive compensation and do not by themselves indicate immediate buying or selling of stock.
Insider Transaction Report
Form 4
Lehr Martin A.
DirectorChief Executive Officer
Transactions
- Award
Stock Option (right to buy)
[F1]2026-02-19+815,000→ 815,000 totalExercise: $2.32Exp: 2036-02-18→ Common Stock (815,000 underlying)
Footnotes (1)
- [F1]The option vests and becomes exercisable over a four-year period. Twenty-five percent (25%) of the option vests and becomes exercisable on February 19, 2027, and the balance vests in equal monthly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.
Signature
/s/ Alex Levit, Attorney-in-Fact|2026-02-23